Clinical trials: Non Alcoholic Fatty Liver
Fatty Liver
Liver Positron Emission Tomography (PET) Study of Non Alcoholic Fatty Liver Disease
The purpose of this study is to evaluate how the liver receives and uses fats for energy. This will help the investigators further understand the physical and chemical processes responsible for Non-Alcoholic Fatty Liver Disease…
- Trial name
- Liver (NCT00949403)
- Testing
- Radio pharmaceuticals C-11 Acetate, and C-11 Palmitate
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Washington University School of Medicine
Fatty Liver, Fatty Liver, Nonalcoholic
The Effects of Zataria Multiflora Boiss (Shirazi's Thyme) on Nonalcoholic Fatty Liver Disease
The aim of this study is to evaluate the effects and safety of a dietary supplement, Zataria multiflora Boiss (Shirazi's Thyme) in the treatment of non alcoholic fatty liver disease (NAFLD).
- Trial name
- ThymeLiv (NCT02983669)
- Testing
- Thyme
- Where
- Iran
- Volunteers
- 86 people
- Sponsor
- Shiraz University of Medical Sciences
Diabetes type2, NASH - Nonalcoholic Steatohepatitis
NASH and Type 2 Diabetes: Role of the Receptor Activator of Nuclear Factor-κB (RANK) and Its Ligand (RANKL)
Non-alcoholic fatty liver diseases (NAFLD) include several entities ranging from simple steatosis to hepatic fibrosis or cirrhosis.
- Conditions
- Diabetes type2, NASH - Nonalcoholic Steatohepatitis, NAFLD
- Trial name
- NADRANK-1 (NCT03968354)
- Testing
- "Collection of additional blood tubes; Biobanking (plasma, liver tissue).
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Alcohol-Related Liver Disease, Drug-Induced Liver Injury
Misocholic Tablets for Non-Viral Elevated Liver Enzymes
Elevated liver enzymes are common laboratory abnormalities that may result from alcohol-related liver disease, drug-induced liver injury, or non-alcoholic fatty liver disease (NAFLD).
- Conditions
- Alcohol-Related Liver Disease, Drug-Induced Liver Injury, Non-alcoholic Fatty Liver Disease
- Trial name
- NCT07833514
- Testing
- Misocholic Tab, Silymarin (Silybum marianum)
- Where
- Vietnam
- Volunteers
- 60 people
- Sponsor
- Hanoi Medical University
Nonalcoholic Fatty Liver Disease, Coronary Artery Disease
The Contribution of Lp-PLA2 Level to the Presence of Coronary Plaques in Patients With Non Alcoholic Fatty Liver Disease
The most common cause of death in patients with NAFLD(Nonalcoholic Fatty Liver Disease) is CAD(Coronary Artery Disease). NAFLD patients have 65% more mortality than general population.
- Trial name
- 0030-10 (NCT01139632)
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Ziv Hospital
Non-Alcoholic Fatty Liver Disease, Non Alcoholic Steatohepatitis
Effect of Patient Demographics, Comorbidities, and Medications on Severity of NASH Fibrosis
Few studies have evaluated an extensive list of possible risk factors for NAFLD for their association with presence and severity of histologic features.
- Trial name
- NCT05357352
- Testing
- NAFLD/NASH
- Where
- United States
- Volunteers
- 263 people
- Sponsor
- Methodist Health System
Non-alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH
This is a randomized, double-blinded study of three doses of MSDC-0602K or placebo given orally once daily to subjects with biopsy proven NASH with fibrosis and no cirrhosis.
- Conditions
- Non-alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis, NASH - Nonalcoholic Steatohepatitis
- Trial name
- EMMINENCE (NCT02784444)
- Testing
- MSDC-0602K
- Where
- 43 sites in United States
- Volunteers
- 392 people
- Sponsor
- Cirius Therapeutics, Inc.
Type 2 Diabetes, Non-alcoholic Fatty Liver Disease
Evaluation of the DPP-4 Inhibitor Sitagliptin in the Treatment of Non-Alcoholic Fatty Liver Disease Using MRI
Participants will be persons with type 2 diabetes who are likely to have fatty liver disease. The investigators think that this medication will reduce fatty liver.
- Trial name
- NCT02263677
- Testing
- Sitagliptin
- Where
- United States
- Sponsor
- University of Missouri-Columbia
Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease
Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH)
This is a Phase 2, multi-center, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy on TVB-2640 in subjects with non-alcoholic steatohepatitis (NASH).
- Trial name
- NCT04906421
- Testing
- TVB-2640
- Where
- 117 sites in United States, Canada and 2 more
- Volunteers
- 168 people
- Sponsor
- Sagimet Biosciences Inc.
Non-Alcoholic Fatty Liver Disease
Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease
This study is a randomized, double-blind, placebo-controlled trial specifically designed to evaluate the preliminary feasibility, initial efficacy and safety of SGLT2 inhibitors for treating NAFLD in adolescents with obesity.
- Trial name
- SHIELD (NCT06355310)
- Testing
- Empagliflozin 10 MG
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Justin Ryder
Non-Alcoholic Fatty Liver Disease
Smartphone App for Non-alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) is a disease spectrum that encompasses excessive liver deposition of fat (NAFL), non-alcoholic steatohepatitis (NASH), and NASH cirrhosis.
- Trial name
- AppLiver (NCT05180760)
- Testing
- Smartphone app use, Standard of care
- Where
- China
- Volunteers
- 260 people
- Sponsor
- The University of Hong Kong
Steatosis of Liver, NASH - Nonalcoholic Steatohepatitis
The Liver in the World Trade Center Health Program General Responder Cohort and Controls
This project investigates whether exposure to the World Trade Center Attack is a risk factor for liver injury.
- Trial name
- NCT03858920
- Testing
- Fibroscan of Liver, Low-dose non-contrast CT
- Where
- United States
- Volunteers
- 340 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Healthy
Study to Estimate How Common it is to Have Genetic Variants Associated With NAFLD
The purpose of this study is to estimate the prevalence of genetic variants associated with liver disease in participants who are known, or are likely to have NAFLD.
- Trial name
- NCT04494360
- Testing
- No intervention
- Where
- 3 sites in United States
- Volunteers
- 830 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Rheumatoid Arthritis, Psoriasis
A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis
The purpose of this study is to investigate experimental medication BMS-986251 taken by mouth in healthy patients and patients with average to very serious Psoriasis (a condition characterized by itchy, dry skin with a scaly…
- Conditions
- Rheumatoid Arthritis, Psoriasis, Ankylosing Spondylitis, Inflammatory Bowel Diseases
- Trial name
- NCT03329885
- Testing
- BMS-986251
- Where
- Netherlands
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Fatty Liver
Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC)
The purpose of this study is to determine if therapeutic modification of insulin resistance or oxidative stress leads to improvement in serum or histologic indicators of liver injury or quality of life.
- Trial name
- TONIC (NCT00063635)
- Testing
- Metformin, Vitamin E
- Where
- 10 sites in United States
- Volunteers
- 173 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Fasting, Non-alcoholic Fatty Liver Disease (NAFLD)
Regulation of FGF21 by Nutritional Challenges
The purpose of this study is to examine how acute nutritional challenges affect levels of several proteins involved in metabolism. These proteins will be measured in blood and fat tissue. This study will have several aims.
- Trial name
- NCT00968747
- Testing
- Fasting, Diet, oral carbohydrate challenge
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Nonalcoholic Fatty Liver
Weight, Energy, Lipids, and the Liver (WELL) Study
The research study is a parallel arm, randomized placebo-controlled clinical trial designed to assess changes in hepatic lipid accumulation, visceral adipose tissue and postprandial lipid, markers of inflammation and energy…
- Trial name
- NCT05199948
- Testing
- Soybean Oil Foods, Palm Oil Foods
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Ohio State University
Type2 Diabetes Mellitus, Nonalcoholic Fatty Liver Disease
Effect of Henagliflozein on Hepatic Fat Content in Patients With T2DM and NAFLD
This study focuses on the effects of Henagliflozein on hepatic fat content in patients with type 2 diabetes mellitus (DM) and nonalcoholic fatty liver disease (NAFLD).
- Trial name
- HHTN (NCT06449833)
- Testing
- Henagliflozein and Metformin, Linagliptin and Metformin
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Zhujiang Hospital
Nonalcoholic Fatty Liver Disease, Type 2 Diabetes
Dapagliflozin in Type 2 Diabetes Mellitus Patients (T2DM) With Nonalcoholic Fatty Liver Disease (NAFLD)
The aim of this study is to evaluate the effect of dapagliflozin on liver function of patient with NAFLD and T2DM.
- Trial name
- NCT05459701
- Testing
- Dapagliflozin 10mg Tab
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Rehab Werida
Non-alcoholic Steatohepatitis (NASH)
A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease
This is a multicenter, randomized, double-blind, placebo-controlled clinical trial in subjects with NAFLD and NASH.
- Trial name
- NCT02927314
- Testing
- CF102
- Where
- 3 sites in Israel
- Volunteers
- 60 people
- Sponsor
- Can-Fite BioPharma
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.